We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Philips Q1 Earnings Miss: Will Weak Outlook Drag the Stock Down?
Read MoreHide Full Article
Koninklijke Philips N.V. (PHG - Free Report) reported earnings of €0.08 cents per share in the first quarter of 2025, which increased from the year-ago quarter’s loss of €1.07 per share.
The company’s sales decreased 1% on a year-over-year basis to €4.1 billion.
Comparable sales declined 2% year over year, including a double-digit decline in China. The 1% growth in Personal Health was more than offset by a 4% decline in Diagnosis & Treatment on the back of a high comparison base. Connected Care sales were in line with the prior year.
Further, Philips’ comparable order intake increased 2% year over year in the reported quarter despite a double-digit decline in China.
Koninklijke Philips N.V. Price, Consensus and EPS Surprise
Sales declined 4% year over year on a comparable basis in growth geographies. Growth geographies primarily decreased as a result of a double-digit decline in China and a high comparison base in Diagnosis & Treatment. The decline was partly offset by an increase in other Growth geographies.
Comparable sales in Mature geographies declined 2% year over year, mainly due to a high comparison base in Diagnosis & Treatment.
PHG’s Segmental Update
Diagnosis & Treatment revenues declined 3% year over year from the year-ago quarter to €1.96 billion. Comparable sales declined 4% year over year, primarily due to a double-digit decline in China, which was offset by strong growth in other regions. While Image Guided Therapy saw solid growth, it was offset by a decline in Precision Diagnosis.
Connected Care revenues increased 1.5% year over year to €1.18 billion. Comparable sales were flat from the year-ago quarter.
Personal Health revenues grew 3% year over year to €811 million. Comparable sales increased 1%, despite a double-digit decline in China, mainly driven by strong growth across the International Region and slight growth in the United States.
Other segment sales amounted to €140 million, down 10.8% on a year-over-year basis.
PHG’s Operating Details
Gross margin expanded 130 basis points (bps) on a year-over-year basis to 45.1% in the reported quarter.
General & administrative expenses, as a percentage of sales, were 3.9%, which expanded 60 bps on a year-over-year basis. Moreover, selling expenses were flat year over year at 26.5%. Research & development expenses increased 100 bps to 11.2%.
Restructuring, acquisition-related and other items amounted to a net gain of €143 million compared with €1,139 million a year ago.
Operating model productivity, procurement and other productivity programs delivered savings of €42 million, €46 million and €59 million, respectively. This resulted in total savings of €147 million.
Phillips’ adjusted EBITA — the company’s preferred measure of operational performance — declined 8.8% year over year to €354 million. EBITA margin contracted 80 bps on a year-over-year basis to 8.6% in the reported quarter.
Diagnosis & Treatment’s adjusted EBITA margin expanded 30 bps on a year-over-year basis to 9.5%.
Connected Care’s adjusted EBITA margin was 3.5% in the reported quarter, which contracted 290 bps year over year.
Personal Health’s adjusted EBITA margin remained in line on a year-over-year basis at 15.2%.
PHG’s Balance Sheet
As of March 31, 2025, Philips’ cash and cash equivalents were €1.19 billion compared with €2.4 billion as of Dec. 31, 2024.
Total debt was €7.568 billion compared with €7.639 billion as of Dec. 31, 2024.
Operating cash outflow was €933 million compared with the year-ago quarter’s operating cash outflow of €171 million.
In the quarter under review, free cash outflow was €1,091 million compared with the year-ago quarter’s free cash outflow of €336 million.
PHG Initiates Weak 2025 Guidance
Philips stock has lost 4.8% year to date compared with the Zacks Medical sector’s decline of 2.4%.
PHG’s 2025 guidance can be negatively impacted by announced tariffs, including US-China and global measures, and the scheduled resumption of US tariffs on July 9. These factors may also put downward pressure on PHG’s shares.
Philips expects to deliver 1-3% of comparable sales growth.
Further, the adjusted EBITA margin is expected to be between 10.8% and 11.3%
Free cash flow is expected to be slightly positive in 2025, after the payout of €1,025 million Philips Respironics recall-related medical monitoring and personal injury settlements in the United States.
Previously, Philips expected to deliver 1-3% of comparable sales growth.
Further, adjusted EBITA margin is expected to be 30-80 bps to 11.8%-12.3%
Image: Bigstock
Philips Q1 Earnings Miss: Will Weak Outlook Drag the Stock Down?
Koninklijke Philips N.V. (PHG - Free Report) reported earnings of €0.08 cents per share in the first quarter of 2025, which increased from the year-ago quarter’s loss of €1.07 per share.
The company’s sales decreased 1% on a year-over-year basis to €4.1 billion.
Comparable sales declined 2% year over year, including a double-digit decline in China. The 1% growth in Personal Health was more than offset by a 4% decline in Diagnosis & Treatment on the back of a high comparison base. Connected Care sales were in line with the prior year.
Further, Philips’ comparable order intake increased 2% year over year in the reported quarter despite a double-digit decline in China.
Koninklijke Philips N.V. Price, Consensus and EPS Surprise
Koninklijke Philips N.V. price-consensus-eps-surprise-chart | Koninklijke Philips N.V. Quote
Sales declined 4% year over year on a comparable basis in growth geographies. Growth geographies primarily decreased as a result of a double-digit decline in China and a high comparison base in Diagnosis & Treatment. The decline was partly offset by an increase in other Growth geographies.
Comparable sales in Mature geographies declined 2% year over year, mainly due to a high comparison base in Diagnosis & Treatment.
PHG’s Segmental Update
Diagnosis & Treatment revenues declined 3% year over year from the year-ago quarter to €1.96 billion. Comparable sales declined 4% year over year, primarily due to a double-digit decline in China, which was offset by strong growth in other regions. While Image Guided Therapy saw solid growth, it was offset by a decline in Precision Diagnosis.
Connected Care revenues increased 1.5% year over year to €1.18 billion. Comparable sales were flat from the year-ago quarter.
Personal Health revenues grew 3% year over year to €811 million. Comparable sales increased 1%, despite a double-digit decline in China, mainly driven by strong growth across the International Region and slight growth in the United States.
Other segment sales amounted to €140 million, down 10.8% on a year-over-year basis.
PHG’s Operating Details
Gross margin expanded 130 basis points (bps) on a year-over-year basis to 45.1% in the reported quarter.
General & administrative expenses, as a percentage of sales, were 3.9%, which expanded 60 bps on a year-over-year basis. Moreover, selling expenses were flat year over year at 26.5%. Research & development expenses increased 100 bps to 11.2%.
Restructuring, acquisition-related and other items amounted to a net gain of €143 million compared with €1,139 million a year ago.
Operating model productivity, procurement and other productivity programs delivered savings of €42 million, €46 million and €59 million, respectively. This resulted in total savings of €147 million.
Phillips’ adjusted EBITA — the company’s preferred measure of operational performance — declined 8.8% year over year to €354 million. EBITA margin contracted 80 bps on a year-over-year basis to 8.6% in the reported quarter.
Diagnosis & Treatment’s adjusted EBITA margin expanded 30 bps on a year-over-year basis to 9.5%.
Connected Care’s adjusted EBITA margin was 3.5% in the reported quarter, which contracted 290 bps year over year.
Personal Health’s adjusted EBITA margin remained in line on a year-over-year basis at 15.2%.
PHG’s Balance Sheet
As of March 31, 2025, Philips’ cash and cash equivalents were €1.19 billion compared with €2.4 billion as of Dec. 31, 2024.
Total debt was €7.568 billion compared with €7.639 billion as of Dec. 31, 2024.
Operating cash outflow was €933 million compared with the year-ago quarter’s operating cash outflow of €171 million.
In the quarter under review, free cash outflow was €1,091 million compared with the year-ago quarter’s free cash outflow of €336 million.
PHG Initiates Weak 2025 Guidance
Philips stock has lost 4.8% year to date compared with the Zacks Medical sector’s decline of 2.4%.
PHG’s 2025 guidance can be negatively impacted by announced tariffs, including US-China and global measures, and the scheduled resumption of US tariffs on July 9. These factors may also put downward pressure on PHG’s shares.
Philips expects to deliver 1-3% of comparable sales growth.
Further, the adjusted EBITA margin is expected to be between 10.8% and 11.3%
Free cash flow is expected to be slightly positive in 2025, after the payout of €1,025 million Philips Respironics recall-related medical monitoring and personal injury settlements in the United States.
Previously, Philips expected to deliver 1-3% of comparable sales growth.
Further, adjusted EBITA margin is expected to be 30-80 bps to 11.8%-12.3%
Philips expects a free cash flow of €900 million.
PHG’s Zacks Rank & Stocks to Consider
Philips currently has a Zacks Rank #3 (Hold).
Affirm (AFRM - Free Report) , ACI Worldwide (ACIW - Free Report) and Baidu (BIDU - Free Report) are some better-ranked stocks that investors can consider in the broader sector. While Affirm sports a Zacks Rank #1 (Strong Buy), ACI Worldwide and Baidu presently carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Affirm shares have lost 16.3% year to date. AFRM is set to report its third-quarter fiscal 2025 results on May 25.
ACI Worldwide shares have gained 4.9% year to date. ACIW is set to report its first-quarter 2025 results on May 08.
Baidu shares have gained 8.2% year to date. BIDU is set to report its first-quarter 2025 results on May 21.